OccuRx appoints Dr Michelle Bradney as Chief Operating Officer

Melbourne, Australia, 15 March 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, today announces Dr Michelle Bradney has been appointed as Chief Operating Officer.

Michelle has over 25 years of progressive global clinical development, clinical operations and medical affairs experience working across Australia, Asia Pacific, Europe and USA. With extensive experience across a range of therapeutic areas, Michelle has provided in-depth scientific, medical and clinical knowledge in both device and pharmaceutical environments.

Michelle has worked in start-up biotechnology companies and global pharmaceutical and device companies where she has led successful IND and IDE approvals across multiple jurisdictions as well as leading their clinical programs and medical affairs operations. Michelle’s experience includes several roles at Allergan in the APAC region alongside experience in leading the strategy and operations for clinical development for ASX listed companies.

Michelle completed a PhD with the Department of Medicine, Melbourne University before moving into the pharmaceutical industry. 

As the Chief Operating Officer at OccuRx, Michelle is responsible to lead and manage OccuRx’s drug development, clinical trial execution and business operations.

“We are delighted to appoint Dr Michelle Bradney as Chief Operating Officer. OccuRx will benefit immensely from Dr Bradney’s strategic input and diverse sector experience as we progress through our clinical development phase.” said Professor Darren Kelly, Executive Chair of OccuRx.

OccuRx has designed a platform of candidate drugs and validated the role of a novel receptor which mediates signalling pathways associated with inflammation and fibrosis. These targeted drugs have established proof of concept as potential treatments for multiple fibrotic diseases including serious and chronic conditions impacting the kidney, lung, eye, and skin. The morbidity and mortality impact of fibrotic diseases is substantial, ultimately causing 45% of all deaths globally.

OccuRx is seeking to combine these innovative therapeutics with biomarkers and genetic analysis to identify the most suitable patients for treatment. Significant breakthroughs are urgently needed in this field, addressing a market worth greater than US$15B annually.